Dubin Glenn
Known title: DirectorCIK: 0001308597
Associated companies
Transaction History
| CCCC | ▲ Buy | Grant | 1,358 | $11K | 4/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 1,687 | $11K | 1/2/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 6,470 | $11K | 10/2/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 3,887 | $11K | 7/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 3,438 | $11K | 4/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 1,725 | $11K | 1/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 1,265 | $11K | 10/3/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 1,372 | $11K | 7/1/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 379 | $10K | 4/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 199 | $6K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 138 | $6K | 10/4/2021 | View on chart |
| CCCC | ▲ Buy | Grant | 157 | $6K | 7/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.